RFA for PTSD Pharmacotherapy: Calling Clinical MDMA?

NIMH has issued an RFA on Clinical Pharmacotherapy for PTSD: Single and Collaborative Studies (R34). From the summary:

Purpose. The sponsoring agencies jointly issue this Funding Opportunity Announcement (FOA) to stimulate research grant applications focused on pharmacological treatments for Post-Traumatic Stress Disorder (PTSD). Medications along a continuum of development and testing (i.e., exploratory compounds ready for human testing, medications used in other areas of medicine and thought to be useful for a new indication (PTSD), and psychiatric medications currently used off-label to treat PTSD) are appropriate as the focus of a research grant application in response to this FOA. The sponsoring agencies seek to advance PTSD pharmacotherapy research by providing resources to better understand feasibility, tolerability, acceptance, safety, possible efficacy and risk/benefit ratios pertaining to symptoms and symptom severity, side effects, and treatment gains in functioning associated with available and novel medications. The sponsoring agencies anticipate the results of such studies will help identify potential medications suitable for larger scale efficacy, effectiveness and services research studies.

Original art from the one and only BioE! is on offer

The artist/scientist blogger occasionally known as bioephemera is offering up a very tasty prize as inducement to contribute to the BioE’s Classroom of Curiosity 2008 DonorsChoose Bloggers challenge.

So here it is, readers: I’m going to do something to persuade you to donate, too. I’m going to give away a painting. A new, original, watercolor painting that I am working on right now. It’s halfway done, in fact. What exactly is this mystery painting I’m doing to thank you, loyal readers? Well, the previous post is a clue. . . more to come.

Very nice. I’m not even sure I can recommend you donate to the DM Blog Readers Challenge (kidding!) with prizes like that floating around.